Tsepamo: DTG Exposure at Conception Associated With Smaller Increase in Incidence of Neural Tube Defects in Updated Analysis

July 21-24, 2019; Mexico City, Mexico
In updated birth outcomes surveillance analysis, NTD prevalence slightly higher with DTG vs non-DTG ART (0.3% vs 0.1%; estimated difference: 0.20% to 0.27%).
Format: Microsoft PowerPoint (.ppt)
File Size: 233 KB
Released: July 24, 2019

Acknowledgements

Provided by USF

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
IAS 2019 Media Partner Logo
Educational grant provided by:
Gilead Sciences
ViiV Healthcare

Related Content

Discussion of key considerations for switching antiretroviral therapy when the patient is pregnant, from Clinical Care Options (CCO)

person default Annette Haberl, MD William R. Short, MD, MPH, AAHIVS Released: November 23, 2022

Dr Yan Zhao discusses data from IDWeek 2022 on long-term benefits of early vs delayed treatment initiation in people with HIV, from Clinical Care Options (CCO)

person default Yan Zhao, MD Released: November 22, 2022

Dr Milosz Parczewski discusses HIV Glasgow 2022 reports on the impact of the war in Ukraine on HIV care in Eastern Europe, from Clinical Care Options (CCO)

Milosz Parczewski, MD, PhD Released: November 22, 2022

Prof Don Smith discusses new HIV data from IDWeek 2022 on long-acting cabotegravir plus rilpivirine in this commentary from Clinical Care Options (CCO)

Don Smith, MD Released: November 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings